HBM7020
Autoimmune Diseases
DiscoveryOut-Licensed
Key Facts
About Harbour BioMed
Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Gavocabtagene autoleucel | Astellas | Phase 1/2 |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |
| I&I Portfolio | Third Arc Bio | Pre-clinical |
| Undisclosed Platform Programs | Zag Bio | Preclinical |
| E-602 | Palleon Pharmaceuticals | IND-Enabling |
| DIASPOT Platform Expansion | DIAsource ImmunoAssays | Commercial & Development |
| Platform Application for Autoimmune Diseases | ALTUCELL | Pre-clinical/Research |